Lentiviral vectors are vectors of choice for many gene therapy applications. Recently, efficient targeting of lentiviral vectors pseudotyped with the Measles virus (MV) glycoproteins has been reported. However, MV antibodies in patients might limit the clinical use of these vectors. We demonstrate here that lentiviral vectors can also be pseudotyped with the glycoproteins of Tupaia paramyxovirus (TPMV), the hemagglutinin (H) and fusion (F) protein. As this animal paramyxovirus has no known close relatives in humans, we do not expect TPMV antibodies in patients. Because TPMV normally does not infect human cells, 'detargeting' from natural receptors is unnecessary. Similar to the MV system, TPMV glycoproteins can mediate targeted cell entry by displaying different single-chain antibodies (scAb) directed against surface molecules on target cells on the viral hemagglutinin. We generated a panel of H and F proteins with truncated cytoplasmic tails and determined the variants that efficiently pseudotyped lentiviral vectors. The B-cell marker CD20 was used as a model antigen, and CD20-targeted TPMV vectors selectively transduced CD20-positive cells, including quiescent primary human B-cells. Lentiviral vectors pseudotyped with targeted TPMV envelope proteins might be a valuable vector choice when systemic application of targeted lentiviral vectors in humans is required.
INTRODUCTION
Gene therapy is a treatment option with great promises, and in the last decades, gene therapy treatments have been suggested for many different diseases. 1 Although there have been encouraging clinical successes in the last few years, there is still no approved gene therapy for any disease. 2 The reasons for the slow progress are manifold, but an important obstacle is a lack of vector technology that allows precise transgene expression in selected target cells after systemic administration of gene therapy vectors. 3, 4 The most desirable way of targeting remains targeting on the entry level as it leaves other tissues or cells completely unaffected. Great progress has been made in the development of recombinant Measles virus (MV) that has been targeted to many different cells types. Targeting of MV is based on the display of specificity domains on the viral hemagglutinin (reviewed in Navaratnarajah et al 5 and Cattaneo 6 ). The MV targeting system is very versatile; multiple different specificity determinants, among them single-chain antibodies (scAb) against carcinoembryonic antigen, CD20, CD38, T-cell receptors, and other domains like epidermal growth factor or echistatin have been successfully used for targeting. 7 However, to achieve full targeting, modifications of the hemagglutinin (H) protein to avoid binding to its natural receptors CD46 and signaling lymphocytic activation molecule (SLAM) are necessary; 8, 9 furthermore, there is at least one other receptor for MV that has not yet been identified. 10 We have also developed an alternative MV targeting system that relies on modifications of an essential cleavage site of the second viral glycoprotein, the fusion (F) protein. 11, 12 MV-based vectors have been tested in preclinical and clinical studies for oncolytic therapy of different forms of cancer, 13 but they are obviously unsuitable for long-term replacement gene therapy as infected cells are killed and there is no integration of the transgene into the genomes of the infected cells. Importantly, it has recently been found that the MV glycoproteins can be used to pseudotype lentiviral vectors. 14 --18 Lentiviruses are attractive vectors for gene therapy of a variety of diseases as they mediate long-term gene expression and can transduce dividing and non-dividing cells. 19 Possible target tissues include different areas of the brain, liver, muscle cells and bone marrow. Although some tissues, mainly hematopoietic stem cells, can be transduced ex vivo and given back to the patient, 20 other tissues, like brain cells, can currently be reached only by direct injection of the vectors. Targeted lentiviral vectors that can be systemically administered to the patient and still only transduce selected cells would be a major improvement in vector technology. 4 A potential disadvantage of the MV system is the presence of neutralizing antibodies in nearly all patients, either by previous infection with wild-type virus or by vaccination. In an animal colon carcinoma model, the therapeutic effect of oncolytic MV vectors was abrogated in animals vaccinated against MV; however, when the MV glycoproteins were replaced by those of the related animal paramyxovirus Canine distemper virus, the oncolytic effect was restored. 21 We have previously characterized the glycoproteins of Tupaia paramyxovirus (TPMV) and could show that they can be targeted by displaying specificity domains on the viral hemagglutinin (H protein) in a similar way to MV. 22 As TPMV has no known relatives in humans, we do not expect neutralizing antibodies against this virus to be present in patients. In contrast to the MV system, in which the H protein needs to be 'detargeted' from its natural receptors, these modifications are unnecessary in TPMV as the virus does not infect human cells.
In this work we show that lentiviral vectors can be pseudotyped with the TPMV glycoproteins when their cytoplasmic tails are truncated. The new vectors can be targeted to selectively transduce CD20-positive cells in a mixed cell population. These vectors might be a valuable alternative when systemic administration of targeted lentiviral vectors is required.
RESULTS
Modification and expression of the TPMV glycoproteins Lentiviral vectors can be pseudotyped with the MV glycoproteins when their cytoplasmic tails are truncated.
14 --16 Accordingly, we generated a panel of TPMV H and F proteins with truncated cytoplasmic tails and characterized their expression in transiently transfected cells using novel antibodies against the protein's ectodomains (Figure 1) . The TPMV H protein is a type II membrane protein with a length of 665 amino acids and has an unusually long cytoplasmic tail of 94 amino acids. 22 We generated eight different TPMV H protein variants with deletions of 20, 40, 50, 60, 70, 80 and 84 amino acids at the aminoterminus of the protein (Figure 1a) . We chose the B-cell surface marker CD20 as a model antigen and therefore displayed an aCD20 scAb on the ectodomain of the H protein. In repeated western blot analyses of transfected cells, we did not observe relevant differences in the expression levels of the H protein ( Figure 1b) . Fusion of the aCD20-scAb to the carboxyterminus of the H protein resulted in a larger molecular mass compared with the unmodified H protein.
As expected, H protein size was reduced in the proteins with truncated cytoplasmic tail (Figure 1b) (Figure 1c) . Additionally, we generated a protein that has the same three-amino-acid cytoplasmic tail (arginine---glycine---arginine) as the recently described MV protein that was used successfully to pseudotype lentiviruses. 14 In western blots, all F protein variants were expressed at a similar level and according to their predicted sizes (Figure 1d ). However, in the proteins with the shortest cytoplasmic tails (FD34, FD35 and F MV3), the F1 fragment was barely detectable, suggesting that in these proteins the F1a/F1b cleavage was more efficient than in the unmodified protein.
Characterization of modified TPMV proteins To investigate the functionality of the modified glycoproteins, we transfected HT1080 cells that stably express CD20 with the wild-type F protein together with all HaCD20 protein variants and unmodified HaCD20 with all F protein variants and monitored the cells for syncytia formation. Unexpectedly, F proteins with a cytoplasmic tail shorter than five amino acids (FD34, FD35 and F MV3) did not support fusion at all, whereas all proteins with longer CTs supported fusion similar to the wild-type F protein (Figure 2a) . These results correlate with the lack of the fusion-triggering F1 fragment in these proteins in western blots (Figure 1d) .
In contrast to the results with the F proteins, we did not observe a similar cutoff with a complete loss of function when the truncated H proteins were tested. However, the degree of fusion Pseudotyping lentiviral vectors with the modified TPMV glycoproteins Next, we generated retargeted vectors that are pseudotyped with the modified proteins. To identify the combination of F and H proteins that results in the highest lentiviral vector titers, we screened the H and F protein variants in all combinations for their ability to mediate gene transfer into CD20-positive cells. Vectors were produced by transfection of 293 T cells with lentiviralexpression plasmids and plasmids encoding the TPMV glycoproteins. 2 days posttransfection, the supernatant of the packaging cells was directly used for transduction of CD20-positive Raji cells. After 48 --72 h, transduced cells showed GFP expression and were analyzed by FACS. Based on the percentage of GFP-expressing cells, the titer (transducing units (t.u.) ml À1 ) was calculated. Titers obtained by screening all F and H protein combinations are shown in Table 1 . We reached the highest titers (10 5 t.u. ml
À1
) with the truncated F variant FD32, which has only 6 amino acids of the cytoplasmic tail left, together with HD80aCD20 that has a cytoplasmic tail length of 14 amino acids. High titers were also obtained with the combinations HD80aCD20/FD18 and HD84aCD20/FD32. Concentration of pseudotyped vectors by low-speed centrifugation increased titers up to about 10 6 t.u. ml À1 . Altogether, there was a trend to higher titers when glycoproteins with shorter cytoplasmic tails were used. However, F proteins with cytoplasmic tails shorter than five amino acids did not lead to infectious vectors. Considering the loss of fusogenicity of these proteins in fusion assays, this result was expected. In contrast to MV, it was possible to pseudotype lentiviral vectors with unmodified TPMV H and F proteins although titers were low. Untargeted TPMV H protein was used as a negative control, truncated MV glycoproteins 14 were used as a positive control and led on average to vector titers in the range of 2 --3 Â 10 4 t.u. ml À1 (data not shown). VSV-G-pseudotyped vectors reached titers much higher than 10 6 t.u. ml À1 that were above the detection limit in this experiment. The optimal TPMV F and H combination identified in this screening was used for all further experiments (HD80aCD20 together with FD32) and will be referred to as LV-TPMVaCD20.
TPMV-pseudotyped vectors selectively transduce CD20-positive cells Next, we wanted to investigate the selectivity of the retargeted pseudotyped vectors. For this purpose the CD20-positive cell line Raji was mixed in a ratio of 1:1 with CD20-negative myeloid cells (K-562) and incubated with different pseudotyped vectors. 72 h posttransduction, CD20-positive cells were stained with an Primary human B cells are efficiently transduced by TPMV-pseudotyped vectors Lentiviral vectors pseudotyped with the MV glycoproteins and targeted to CD20 are able to efficiently transduce primary B cells, a cell type that is difficult to transduce with traditional vectors.
14 To test whether the novel TPMV vectors can also transduce this cells type, we isolated primary human B cells from peripheral blood mononuclear cells, activated them with a cytokine cocktail for 48 h and incubated them with the pseudotyped vectors. Incubation with the cytokine cocktail resulted in expression of the activation marker CD69 on almost all CD20/CD19-double-positive B cells (data not shown). After 72 h, cells were stained for CD19 and CD20, and the percentage of GFP/CD19/CD20-triple positive cells was determined by FACS. As expected, there was only low transduction efficiency with the VSV-pseudotyped vectors (13.2%), even with a MOI of 100 (Figure 4a , bottom row). Transduction with LV-TPMVaCD20 was much more efficient and resulted in transduction of 65% of the CD19 þ /CD20 þ cells (Figure 4a , top row). As in previous work with LV-MVaCD20, 14 we observed a reduction of CD20 expression in cells transduced with LV-TPMVaCD20 and LV-MVaCD20. The mechanism is not clear; masking of CD20 on the targeted cells by the CD20 antibody, downregulation of CD20 on the target cells 23 or fusion of some target cells by the vector particles ('fusion from without', 24 ) are possible explanations. Lentiviruses were produced with all combinations of the modified TPMV glycoproteins. The screening identified the variants resulting in the highest vector titers: TPMV-HD80aCD20 together with FD32. All further experiments were performed with these variants. . 72 h after transduction, the mixed population was stained against CD20 and GFP expression was analyzed by FACS. The CD20-targeted LVs selectively transduce CD20 þ cells. In contrast, the VSV-Gpseudotyped LV transduced both cells types, but with very low efficiency. Untargeted TPMV-pseudotyped vectors were used as a negative control. GFP, green fluorescent protein; LV, lentiviral vector; VSV-G, vesicular stomatitis virus G.
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As a next step, we investigated if LV-TPMVaCD20 can also transduce quiescent primary human B cells. Immediately after isolation, the cells were incubated with different pseudotyped vector types with a MOI of 1.0. Remarkably, 45.2% of quiescent B cells were transduced by the TPMV-pseudotyped vector (Figure 4b , top row). As expected, there was virtually no transduction with the VSV-vectors, even not with a MOI of 100 (o1%, Figure 4b , bottom row). For both activated and quiescent B cells, the TPMV-vectors were more efficient than the MV-vectors that were used as positive control.
DISCUSSION
The recently developed MV-pseudotyped lentiviral vectors combine the versatile MV targeting system with the advantages of lentiviral vectors (reviewed in Buchholz et al 25 ) . However, as MV antibodies in patients might neutralize MV-based vectors, we sought for alternative paramyxoviruses that might be useful for vector development. To avoid the problem of neutralizing antibodies, animal paramyxoviruses might be a possible alternative to human viruses, although several animal paramyxoviruses have close human relatives that are at least partially crossreactive. 26 TPMV is related to the Morbilliviruses and Henipaviruses, but is genetically too different to be assigned to these genera. 27 The TPMV glycoproteins are related to the MV glycoproteins but have some uncommon properties: 22 the F protein cleavage site is different from all other paramyxoviruses and is activated by a yet unidentified protease. We recently found that a significant fraction of the F1 protein is further cleaved into an F1a and F1b fragment (Enkirch and Springfeld, unpublished results), similar to the MV F protein. 28 The H protein has a cytoplasmic tail that is with 94 amino acids, considerably longer than those of all other paramyxoviruses. Importantly, we found that targeting of the TPMV glycoproteins with a CEA scAb in analogy to MV is possible. In this study, we demonstrate that a aCD20-scAb can also be used for targeting, adding evidence that the TPMV targeting system is as versatile as the MV system. As most cell types targeted for gene therapy express unique surface antigens against which scAbs can be generated, our results open the exciting perspective of targeted lentiviral transduction of any target tissue after systemic administration of gene therapy vectors.
Unmodified MV glycoproteins are not incorporated into lentiviral vectors, but when the glycoproteins were truncated at their cytoplasmic tails, pseudotyping of lentiviral vectors was possible. For the F protein, a truncation of the cytoplasmic tail to Figure 4 . TPMV-pseudotyped LVs efficiently transduce primary human B lymphocytes. Primary human B cells (CD20 þ /CD19 þ ) were isolated from human peripheral blood mononuclear cells and transduced after activation with a cytokine cocktail (a) or immediately after isolation (b). GFP-expression was analyzed 48 h after transduction by FACS. Both aCD20-vectors (TPMV and MV) were able to transduce activated and quiescent primary B cells with high efficiency (MOI 1). Almost no transduction was observed for LV-VSV-G for quiescent B cells and only 13% transduction efficiency for activated B cells, even at a MOI of 100. GFP, green fluorescent protein; LV, lentiviral vector; VSV-G, vesicular stomatitis virus glycoprotein.
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three amino acids was found to result in the highest vector titers. 14, 15 Similar results had been obtained previously with the F protein of Sendai virus that had a cytoplasmic tail truncation to four amino acids. 29 For the MV H protein, conflicting results have been published: although one group found a truncation to 16 amino acids most effective, 14 another group reported a truncation to 10 amino acids to be optimal. 15 As the cytoplasmic tails of the MV and TPMV glycoproteins have no sequence similarities, it was not possible to directly transfer the results obtained for MV to TPMV. For the F protein, we found that a truncation of the cytoplasmic tail to three amino acids as in the MV study completely abrogated the fusion support function of the protein. Accordingly, no infectious vectors could be obtained with this protein. An exchange of the TPMV F cytoplasmic tail with the truncated MV cytoplasmic tail did also not lead to a functional protein. Finally, the F protein variant with a six-amino acid tail (FD32) resulted in the highest vector titers. For the H protein, we found that truncations of the long cytoplasmic tail were surprisingly well tolerated. Although the fusogenicity of the protein was reduced when the cytoplasmic tail was truncated, there was no complete loss of function when a certain tail length was reached. The optimal tail length for the generation of pseudotyped lentiviral vectors was 14 amino acids (HD80) and therefore in the range of those reported for MV. Finally, we reached vector titers similar to those in the MV system. Compared with lentiviral vectors pseudotyped with VSV, these titers are still low, and previous to clinical trials with theses vectors it will probably be necessary to further improve the production measures to generate titers sufficient to obtain an adequate ratio of vector particles and target cells in vivo. Recent results that showed efficient and selective transduction of target cells after systemic administration of MV-pseudotyped targeted lentiviral vectors via the tail vein in a tumor mouse model are encouraging. 30 In contrast to the MV system, our attempts to increase vector titers by using different ratios of the F and H plasmids during vector production were not successful (data not shown). A more detailed understanding of the requirements for glycoprotein incorporation into lentiviral particles will probably be necessary to make additional modifications of the TPMV glycoproteins that can further increase vector titers possible.
Although lentiviral vectors pseudotyped with VSV-G can transduce most target cells, there are notable exceptions, among them quiescent primary human lymphocytes that are not transduced even when a high MOI is used. The significant importance of these cell types for gene therapy approaches for inherited immunodeficiencies, cancer and autoimmune diseases has recently been reviewed. 31 Lentiviruses pseudotyped with the MV glycoproteins can transduce these cells efficiently; unexpectedly, binding to both natural receptors of vaccine strain MV, CD46 and SLAM, seems to be necessary. 32, 33 However, lentiviruses pseudotyped with a mutated MV H protein unable to mediate entry via CD46 or SLAM, but targeted with a aCD20-scAb could also be used to transduce quiescent B cells.
14 It has been speculated that residual binding of the H protein to CD46/SLAM or binding of the scAb to CD20 might induce changes in the target cells that make them susceptible to lentiviral transduction. 25 Our results with lentiviruses that carry the same aCD20-scAb on the TPMV glycoproteins confirm that binding of the scAb to CD20 is sufficient to mediate transduction of these cells.
Our results show that it is possible to generate lentiviral vectors with paramyxovirus envelope proteins of non-human viruses that will not be neutralized by preexisting antibodies in patients. TPMV H was only the second paramyxovirus hemagglutinin that could be targeted with scAb after MV; 22 recently the Canine distemper virus envelope was also successfully used for targeting. 21 TPMV vectors will certainly induce neutralizing antibodies when administered systemically to patients. As in many cases repeated administration of gene therapy vectors will probably be necessary for efficient transduction of the target tissue, it might be reasonable to further pursuit the identification of other animal paramyxovirus envelope proteins that, like TPMV, can be targeted and used to pseudotype lentiviral vectors.
MATERIALS AND METHODS

TPMV-expression plasmids
Cloning of the unmodified TPMV H and F protein has been described previously. 22 The expression plasmid pCG-TPMV-HaCD20 that encodes a fusion protein of TPMV H and a scAb to human CD20 was generated by amplification of the open reading frame of the aCD20-scAb from the plasmid pCGHaCD20, 34 using the forward primer 5 0 -GGGGCGCGCAGGTT CAGCTGGTCCAG-3 0 that inserts a BssHII site to the 3 0 end of the H open reading frame and a reverse primer in the backbone of the pCG vector. After cutting with BssII and XbaI, the fragment was cloned into the plasmid pCG-TPMV-HXaCEA, 22 thereby exchanging the aCEA-scAb against the aCD20-scAb. TPMV H cytoplasmic tail variants were generated by PCR-cloning using primers that deleted the desired amino acids and introduced a new start codon. The F protein variants were constructed using primers that introduced a stop codon at the desired position and deleted the following amino acids. The TPMV-F-MV3-expression plasmid was generated using a primer that introduced the three cytoplasmic tail amino acids (arginine---glycine---arginine) followed by a stop codon.
Cell lines
293 T (ICLC HTL04001) cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% glutamine. Raji (ATCC CCL-86) and K-562 (ATCC CCL-243) were grown in RPMI 1640 supplemented with 10% FCS and 1% glutamine. HT1080-CD20 cells have been described previously. 34 They were grown in DMEM supplemented with 10% FCS, 1% glutamine and 3 mg ml À1 puromycin.
Generation of antisera and western blot analysis
The peptide (C)SEDSTHDQGPGVEGTSRNHKGK, corresponding to TPMV H amino acids 215 --237, was synthesized by the Mayo Clinic protein core facility, coupled to keyhole limpet hemocyanin, and used to generate the peptide antiserum aH ecto in rabbits (Cocalico Biologicals, Reamstown, PA, USA). Antiserum against the peptide (C)ELEMDKTQKALDRSNKIL, corresponding to TPMV F amino acids 462 --480 (aF ecto ), was also generated in rabbits (Peptide Specialty Laboratories, Heidelberg, Germany). For detection of TPMV glycoprotein variants, 293 T cells were transfected with the appropriate pCG-expression plasmids using Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. After 48 h, the cells were lysed in RIPA-buffer (150 mM NaCl,, 50 mM Tris-HCl, pH 7.5, 1% Nonidet P40, 0.5% sodiumdeoxycholate and 1% sodium dodecyl sulfate) with complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Cell lysates were clarified by centrifugation for 10 min at 5000 g at 4 1C and protein concentration of the total cell lysates was determined by Bradford assay accordingly to the manufactures instructions (Roti-Quant, Carl Roth þ Co. KG, Karlsruhe, Germany). Subsequently, the lysates were mixed in a ratio of 6:1 with 6 Â SDS sample buffer (0.35 M Tris-Cl/0.28% SDS, pH 6.8, 30% glycerol, 10% sodium dodecyl sulfate, 9.3% DTT and 0.012% bromophenol blue) and denatured by incubation for 5 min at 95 1C. Afterwards, 10 mg of the total protein were applied to 10% sodium dodecyl sulfate-polyacrylamide electrophoresis gels and blotted onto polyvinylidenfluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were incubated with aF ecto or aH ecto (1:1000). As secondary antibody, a horseradish peroxidase-conjugated anti-rabbit antibody was used (1:2000, polyclonal swine anti-rabbit immunoglobulins/HRP, Dako Cytomation, Glostrup, Denmark). For detection, the membranes were subjected to Amersham ECL western blotting detection reagent (GE Healthcare, Munich, Germany).
Syncytia assays
For syncytia assays, HT1080-CD20 cells were co-transfected in six-well plates (3.5 Â 10 5 cells per well) with a total amount of 3.9 mg of plasmid 
FACS analysis
FACS analysis was performed on a BD LSRII flow cytometer (Becton Dickinson, Heidelberg, Germany). Raji and K-562 cells were washed twice in 500 ml FACS washing buffer (phosphate-buffered saline, 1% FCS and 0.1% NaN 3 ) and finally resuspended in 100 ml phosphate-buffered saline/ 1% paraformaldehyde. To detect CD20-positive cells, the cells were incubated with a 1:10 dilution of the mouse anti-human CD20/PE-Cy5 antibody (BD Pharmingen, Heidelberg, Germany) after the first washing step. After 20 min at 4 1C, the antibody solution was removed and the cells were washed twice and fixed as described before. For detection of CD19-positive cells, the mouse anti-human CD19/PE antibody (DakoCytomation, Hamburg, Germany) was used. The data were analyzed with the FCS-Express V3 (De Novo Software, Los Angeles, CA, USA) program.
Generation of lentiviral vectors
For screening of all F-and H-combinations, vector particles were generated by transfection of 293 T cells using polyethylene-imine (Sigma-Aldrich, Munich, Germany) with 1.73 mg. of the lentiviral transfer vector plasmid pSEW, 35 1.65 mg of the packaging plasmid pCMVDR8.9 36 and 0.27 mg each of the TPMV H and F protein variant expression plasmids. 24 h before transfection, 2.0 Â 10 6 cells per well were seeded into a single well of a six-well plate. On the day of transfection, the medium was replaced by 0.5 ml DMEM ( þ 1% glutamine). The plasmids were mixed with 17.7 ml of 5% (wt/vol) glucose. In a different tube, 17.7 ml of 5% glucose was mixed with 4 ml of 18 mM polyethylene-imine. Both solutions were incubated for 10 min at room temperature, then combined, mixed and incubated again at room temperature. After 10 min, the volume of the mixture was increased with 1 ml of DMEM ( þ 1% glutamine) and then added to the cells. Finally, 100 ml of FCS per well was added to the cells 5 --6 h after transfection. 48 h later, the cell supernatant containing the viral particles was collected and 150 ml were directly used for transduction. The resulting vectors were titrated on Raji cells. For MV-pseudotyped vectors, 0.15 mg H plasmid and 0.46 mg F plasmid were used, for VSV-G-pseudotyped vectors, 0.6 mg of pMD.G2 (Didier Trono, Tronolab, Lausanne, Switzerland) was used.
For all other experiments, vector stocks were produced by transfection using 70 ml polyethylene-imine and 310 ml glucose for a T175 flask. One day before transfection, 1.5 Â 10 7 293 T cells were seeded and transfected with 28.7 mg of packaging plasmid, 30.2 mg of transfer vector plasmid and 5.3 mg each of TPMV-H-and F-expression plasmids. The MV H-protein-expression plasmid 4 was used in an amount of 2.6 mg and the MV F protein plasmid was used in an amount of 8 mg. For VSV-G-pseudotyped vectors, 10.6 mg pMD.G2 plasmid was used. To the transfection mixture 2.2 ml DMEM ( þ 1% glutamine) was added. For concentrating the vector particles, the supernatant was collected after 48 h, filtered (0.45 mm filter) and centrifuged by low-speed centrifugation over a sucrose-cushion (20% wt/vol, 4000 g for 24 h at 4 1C). The supernatant was discarded and the pellet was resuspended in 60 ml Opti-MEM (200 ml for VSV-Gpseudotyped vectors).
Transduction of different cell lines
For the initial screening of all TPMV-F and H protein combinations, 2.0. Â 10 4 Raji cells were seeded on the day of transduction into a single well of a 96-well plate. The vector stocks were serially diluted in steps of 1:10 in a total volume of 200 ml. Of these dilutions, 150 ml were added to the cells together with 4 ng ml À1 protamine sulfate and incubated for 3 h at 37 1C. Then, 100 ml fresh medium was added to the cells. After 72 h, GFP-positive cells were determined by FACS analysis and the titer was calculated. For all other experiments, 1.0 Â 10 5 cells (Raji) were seeded into a single well of a 48-well plate. Serial dilutions were performed in a total volume of 300 and 250 ml were added to the cells together with 4 ng ml À1 protamine sulfate. After 3 h, 0.7 ml fresh medium was added to the cells. For the transduction of the mixed cell population, 5.0 Â 10 4 Raji cells together with 5.0 Â 10 4 K-562 cells were seeded into a single well of a 48-well plate and transduced as described above.
Isolation of primary human B cells
Primary human B cells were isolated from fresh human blood using the Dynal B-cell negative isolation kit (Invitrogen) as suggested by the manufacturer instructions. Isolated B cells were either used immediately for transduction (in RPMI 1640, 10% FCS, 1% glutamine, 0.5% streptomycine/penicilline and 25 mmol l À1 HEPES) or activated for 48 h in this medium together with 300 ng ml À1 CD40 ligand, 50 ng ml À1 interleukin-2, 10 ng ml À1 interleukin-4 and 10 ng ml À1 interleukin-10 (R&D Systems, Wiesbaden, Germany). Stimulated B cells were detected by an antibody against the activation marker CD69 (mouse anti-human CD69/FITC, DakoCytomation). For transduction, the isolated B cells were seeded into a single well of a 48-well plate (5.0 Â 10 4 cells per well) together with the virus particles in a total volume of 300 ml and with 4 ng ml À1 protamine sulfate. This was followed by centrifugation at 430 g for 30 min at 32 1C. Subsequently, the cells were incubated at 37 1C. Next day, 500 ml per well medium (as described above) was added to the cells and 72 h after transduction, the fraction of GFP-positive cells was determined by FACS analysis.
